JP2019108360A5 - - Google Patents

Download PDF

Info

Publication number
JP2019108360A5
JP2019108360A5 JP2019035095A JP2019035095A JP2019108360A5 JP 2019108360 A5 JP2019108360 A5 JP 2019108360A5 JP 2019035095 A JP2019035095 A JP 2019035095A JP 2019035095 A JP2019035095 A JP 2019035095A JP 2019108360 A5 JP2019108360 A5 JP 2019108360A5
Authority
JP
Japan
Prior art keywords
amino acid
peptide
group
acid selected
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019035095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019108360A (ja
JP7303640B2 (ja
Filing date
Publication date
Priority claimed from JP2015501673A external-priority patent/JP2015514070A/ja
Application filed filed Critical
Publication of JP2019108360A publication Critical patent/JP2019108360A/ja
Publication of JP2019108360A5 publication Critical patent/JP2019108360A5/ja
Application granted granted Critical
Publication of JP7303640B2 publication Critical patent/JP7303640B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019035095A 2012-03-21 2019-02-28 Ｔｆｐｉ阻害剤および使用方法 Active JP7303640B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613865P 2012-03-21 2012-03-21
US61/613,865 2012-03-21
JP2015501673A JP2015514070A (ja) 2012-03-21 2013-01-31 Ｔｆｐｉ阻害剤および使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015501673A Division JP2015514070A (ja) 2012-03-21 2013-01-31 Ｔｆｐｉ阻害剤および使用方法

Publications (3)

Publication Number Publication Date
JP2019108360A JP2019108360A (ja) 2019-07-04
JP2019108360A5 true JP2019108360A5 (enExample) 2019-10-03
JP7303640B2 JP7303640B2 (ja) 2023-07-05

Family

ID=47682077

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015501673A Pending JP2015514070A (ja) 2012-03-21 2013-01-31 Ｔｆｐｉ阻害剤および使用方法
JP2019035095A Active JP7303640B2 (ja) 2012-03-21 2019-02-28 Ｔｆｐｉ阻害剤および使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015501673A Pending JP2015514070A (ja) 2012-03-21 2013-01-31 Ｔｆｐｉ阻害剤および使用方法

Country Status (16)

Country Link
US (3) US8962563B2 (enExample)
EP (1) EP2827883B1 (enExample)
JP (2) JP2015514070A (enExample)
KR (2) KR20140143191A (enExample)
CN (3) CN109134614A (enExample)
AU (2) AU2013235741C1 (enExample)
BR (1) BR112014022435B1 (enExample)
CA (1) CA2867363C (enExample)
DK (1) DK2827883T3 (enExample)
ES (1) ES2733958T3 (enExample)
HR (1) HRP20191160T1 (enExample)
HU (1) HUE046572T2 (enExample)
LT (1) LT2827883T (enExample)
NZ (3) NZ724133A (enExample)
SI (1) SI2827883T1 (enExample)
WO (1) WO2013141965A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
IL247448B (en) 2014-02-28 2022-09-01 3B Pharmaceuticals Gmbh Peptides and methods of use
US11279771B2 (en) 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
EP3455636B1 (en) * 2016-05-13 2023-08-23 The Scripps Research Institute Compositions and methods for anti-thrombotic and hemostatic therapies
KR20220032078A (ko) * 2019-07-08 2022-03-15 쓰리비 파마슈티컬스 게엠베하 섬유모세포 활성화 단백질 리간드를 포함하는 화합물 및 그의 용도
EP3997103B9 (en) 2019-07-08 2025-02-26 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
TW202140513A (zh) * 2020-02-22 2021-11-01 日商Ｊｃｒ製藥股份有限公司 人類運鐵蛋白受體結合肽
CN117835998A (zh) * 2021-04-18 2024-04-05 兰巴姆医疗技术有限公司 促凝血肽及其应用
AU2023232562A1 (en) 2022-03-08 2024-09-05 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
US20240216504A1 (en) * 2022-12-30 2024-07-04 Dong Kyu Jin Method for preventing or treating of hemathrosis

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5733175A (en) 1980-07-31 1982-02-23 Mitsubishi Electric Corp Transmitter for signal of elevator
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS607193A (ja) 1983-06-25 1985-01-14 古河電気工業株式会社 回路基板用半田付炉
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5622988A (en) 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK146190D0 (da) 1990-06-15 1990-06-15 Novo Nordisk As Hidtil ukendte forbindelser
US5849703A (en) 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
JPH067193A (ja) 1991-11-29 1994-01-18 Teijin Ltd モノクローナル抗体
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
WO1994002172A1 (en) 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
JP3929484B2 (ja) 1993-09-14 2007-06-13 ジェネンテック・インコーポレーテッド エコチンおよびその同族体を含む医薬的組成物
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
PT1489097E (pt) 1994-01-11 2012-01-04 Dyax Corp Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
EP1005551A2 (en) 1997-01-31 2000-06-07 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US20050032690A1 (en) 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
AU2683699A (en) 1998-02-18 1999-09-06 Harbor-Ucla Research And Education Institute Antimicrobial peptides and derived metapeptides
JP2000128803A (ja) 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
EP1212073A4 (en) 1999-07-23 2003-09-03 Scripps Research Inst Method for measuring coagulant factor activity in whole blood
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2001035903A2 (en) 1999-11-16 2001-05-25 Kurnick, James, T. Compositions and methods for regulating tumor-associated antigen expression
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
EP1593389A1 (en) 2000-05-10 2005-11-09 Novo Nordisk Health Care AG Pharmaceutical composition comprising a factor VIIa and a factor XIII
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
AU2002230390A1 (en) 2000-10-05 2002-04-29 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
HUP0400976A3 (en) 2001-07-20 2006-01-30 Novo Nordisk Healthcare Ag Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides
US20030040480A1 (en) 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
ES2307779T3 (es) 2001-08-16 2008-12-01 Baxter International Inc. Formulaciones de microparticulas a base de propelentes.
US20080026068A1 (en) 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
EP1432447A2 (en) 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
CN1176943C (zh) * 2001-10-08 2004-11-24 复旦大学 新型重组人组织因子途径抑制物活性肽及其制备方法
WO2003039579A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20050214836A1 (en) 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
EP1403638A1 (en) 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
WO2004063337A2 (en) 2003-01-07 2004-07-29 Dyax Corporation Kunitz domain library
AU2003229678A1 (en) 2003-04-15 2004-11-04 Dirk Koczan Method for diagnosing rheumatoid arthritis or osteoarthritis
US20070092452A1 (en) 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
BRPI0412735A (pt) 2003-07-18 2006-09-26 Baxter Int métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP2007508240A (ja) 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
WO2005024006A2 (en) 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
EP1668371B1 (en) 2003-09-24 2012-05-09 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis using tfpi-2 protein
DE112004002385D2 (de) 2003-09-29 2006-08-31 Hemoteq Gmbh Biokompatible, biostabile Beschichtung von medizinischen Oberflächen
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
KR20060118486A (ko) 2003-11-20 2006-11-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｘｉ의 치료적 사용
US20050181978A1 (en) 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
JP4885729B2 (ja) 2003-11-20 2012-02-29 サノフィ パストゥール インコーポレイテッド 百日咳毒素を精製する方法およびそれに有用なペプチド
US20050147689A1 (en) 2003-12-30 2005-07-07 Egilmez Nejat K. Method for inhibiting the growth of gastrointestinal tract tumors
EA012370B1 (ru) 2004-02-28 2009-10-30 Хемотек Аг Стент с биосовместимым покрытием и способы его изготовления
US20090053193A1 (en) 2004-05-11 2009-02-26 Novo Nordisk Healthcare A/G Use of Factor VIIa for the Treatment of Burn Trauma
WO2005112893A1 (en) 2004-05-12 2005-12-01 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005115442A1 (en) 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
CN1984664B (zh) 2004-05-27 2013-07-24 巴克斯特国际公司 应用硫酸多糖治疗出血障碍的方法
US20080058255A1 (en) 2004-06-21 2008-03-06 Novo Nordisk Healthcare A/G Glycosylation-Disrupted Factor VII Variants
US20090004175A1 (en) 2004-07-16 2009-01-01 Novo Nordick Health Care A/G Methods for Optimizing Forming Vlla-Based Hemostatic Treatment
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム
EP1855712A2 (en) 2005-02-28 2007-11-21 Novo Nordisk Health Care AG Fxiii variants with improved properties
DE602006021290D1 (de) 2005-03-04 2011-05-26 Univ Illinois Modulator von coagulationskaskaden und fibrinolytischen kaskaden
EP1885335A1 (en) 2005-04-27 2008-02-13 BAXTER INTERNATIONAL INC. (a Delaware corporation) Surface-modified microparticles and methods of forming and using the same
KR20080008364A (ko) 2005-05-05 2008-01-23 헤모텍 아게 관 스텐트의 전면 코팅
WO2006128497A1 (en) 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
EP1919499A2 (en) 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
GB0525999D0 (en) 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
JP5075131B2 (ja) 2006-02-09 2012-11-14 ビー．ブラウン メルズンゲン アーゲー 折り畳まれたバルーンに被膜する方法
US20070192033A1 (en) 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
US9096839B2 (en) 2006-04-26 2015-08-04 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
US20070281031A1 (en) 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP1892303A1 (en) 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
EP1895436A1 (en) 2006-08-31 2008-03-05 Silicos NV Method for evolving molecules and computer program for implementing the same
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
ES2683948T3 (es) 2007-02-23 2018-09-28 Baxalta GmbH Métodos de procedimiento para la purificación de fucoidano a partir de extractos de algas marinas
EP1972687A1 (en) 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
BRPI0816837B1 (pt) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
WO2009080054A1 (en) 2007-12-21 2009-07-02 Ifxa A/S Protease inhibitor
FR2934052B1 (fr) 2008-07-17 2011-11-25 Stago Diagnostica Dosage de l'activite du facteur tissulaire circulant
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
KR100994996B1 (ko) 2008-08-06 2010-11-18 한국과학기술연구원 페난트렌 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
LT2379096T (lt) 2008-12-19 2019-12-27 Baxalta GmbH Tfpi inhibitoriai ir vartojimo būdai
EP2547355B1 (en) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
JP6170903B2 (ja) * 2011-04-01 2017-07-26 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6153985B2 (ja) 2015-10-16 2017-06-28 株式会社スクウェア・エニックス ビデオゲーム処理プログラム、ビデオゲーム処理システム及びビデオゲーム処理方法

Similar Documents

Publication Publication Date Title
JP2019108360A5 (enExample)
US20240327461A1 (en) Apelin polypeptides
DK2547692T5 (en) PEPTID DERIVATIVES, PREPARING thereof, AND APPLICATIONS THEREOF
US6046167A (en) Peptide YY analogs
JP2011518179A5 (enExample)
JP2017537893A5 (enExample)
JP2010515686A5 (enExample)
HRP20191160T1 (hr) Tfpi inhibitori i postupci upotrebe
CN102348462B (zh) Tfpi抑制剂和使用方法
AU2010216372B2 (en) Cytotoxic conjugates having neuropeptide Y receptor binding compound
ES2855169T3 (es) Conjugados de polipéptido-anticuerpo derivados de aprotinina
JP2023029957A (ja) 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
CN104781276A (zh) 肽-树枝状聚合物结合物及其用途
WO2015123679A1 (en) Hydrophilic antibody-drug conjugates
US11529424B2 (en) Synthetic bioconjugates
TW201114434A (en) Oxytocin receptor agonists
JP2026032056A5 (enExample)
CN102190708B (zh) 一种桶形α芋螺多肽Bt1.3及其应用
JP2020532496A5 (enExample)
US7314858B2 (en) Retrocyclins: antiviral and antimicrobial peptides
JP2007506713A (ja) 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用
JP2009540842A5 (enExample)
CN110799547B (zh) 用于治疗、改善或预防神经系统相关病症的化合物及其用途
WO2013134249A1 (en) Adipose tissue targeted peptides
EP1590458A2 (en) Bradykinin b2 receptor antagonist peptide from amphibian skin